Literature DB >> 328408

Suppression of cell-mediated immunity by metronidazole.

D I Grove, A A Mahmound, K S Warren.   

Abstract

Metronidazole administered orally in doses of 20 and 200 mg/kg daily suppressed granuloma formation around Schistosoma mansoni eggs which were injected intravenously and lodged in the pulmonary microvasculature of mice. The same doses did not suppress granuloma formation in animals which had previously been sensitized to the eggs. Nonspecific granulomatous inflammation around divinyl benzene copolymer beads was unaffected by the drug. In a daily dose of 20 mg/kg, metronidazole inhibited delayed footpad reactions to soluble schistosome egg antigen, but 200 mg/kg on alternate days failed to suppress skin allograft rejection. The drug appears to suppress selectively some aspects of cell-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 328408     DOI: 10.1159/000231857

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  18 in total

Review 1.  Results of pouch surgery after ileo-anal anastomosis: the implications of pouchitis.

Authors:  B J Fozard; J H Pemberton
Journal:  World J Surg       Date:  1992 Sep-Oct       Impact factor: 3.352

2.  Closure of refractory perineal Crohn's lesion. Integration of hyperbaric oxygen into case management.

Authors:  E W Nelson; D E Bright; L F Villar
Journal:  Dig Dis Sci       Date:  1990-12       Impact factor: 3.199

3.  Double blind, placebo controlled trial of metronidazole in Crohn's disease.

Authors:  L Sutherland; J Singleton; J Sessions; S Hanauer; E Krawitt; G Rankin; R Summers; H Mekhjian; N Greenberger; M Kelly
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

4.  The use of topical 10% metronidazole in the treatment of non-healing pilonidal sinus wounds after surgery.

Authors:  Efthymios Ypsilantis; Emin Carapeti; Shirley Chan
Journal:  Int J Colorectal Dis       Date:  2015-05-24       Impact factor: 2.571

Review 5.  Management of perianal Crohn's disease.

Authors:  A Allan; M R Keighley
Journal:  World J Surg       Date:  1988-04       Impact factor: 3.352

6.  Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis.

Authors:  R W Chapman; W S Selby; D P Jewell
Journal:  Gut       Date:  1986-10       Impact factor: 23.059

Review 7.  Current therapy of inflammatory bowel disease in children.

Authors:  Paul A Rufo; Athos Bousvaros
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

8.  Miconazole prolongs murine skin graft survival.

Authors:  Y H Thong; A Ferrante
Journal:  Clin Exp Immunol       Date:  1979-01       Impact factor: 4.330

9.  Reactivation of arthritis induced by small bowel bacterial overgrowth in rats: role of cytokines, bacteria, and bacterial polymers.

Authors:  S N Lichtman; J Wang; R B Sartor; C Zhang; D Bender; F G Dalldorf; J H Schwab
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

10.  Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability.

Authors:  G R Davies; M E Wilkie; D S Rampton
Journal:  Dig Dis Sci       Date:  1993-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.